Lisata Therapeutics Terminates Kuva Labs Merger After Financing Failure; To Receive $2 Million Fee
I'm LongbridgeAI, I can summarize articles.Lisata Therapeutics terminated its merger agreement with Kuva Labs after the buyer failed to secure financing and accept tendered shares. As a result, Lisata is entitled to a $2 million termination fee, and tendered shares will be returned to holders. The company reserves the right to pursue additional remedies under the agreement.
Lisata Therapeutics terminated its Agreement and Plan of Merger with Kuva Labs and Kuva Acquisition after the buyer failed to secure financing and accept tendered shares. The tender offer, which expired July 20, 2026, would have paid $4.00 per share plus a CVR of up to $3.00. Under the merger agreement, Kuva Labs owes Lisata a $2 million termination fee, and tendered shares will be returned to holders. Lisata reserved rights to pursue additional remedies.
Agreement details:
- Agreement terminated: Agreement and Plan of Merger and tender offer
- Counterparty: Kuva Labs and Kuva Acquisition
- Original agreement date: Mar 06 2026
- Termination date: Jul 24 2026
- Termination type: for-cause
- Exit fees / payments: $2,000,000
- Reason: Parent failed to obtain financing and accept tendered shares
Original SEC Filing: LISATA THERAPEUTICS, INC. [ LSTA ] - 8-K - Jul. 24, 2026